Publications
Find out some of the most recentpublications from our group
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study
Future Oncol – 2023 Jul
doi: 10.2217/fon-2023-0406 – PubMed ID: 37577810
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by GONO Foundation
J Clin Oncol. 2023 Aug 3
doi: 10.1200/JCO.23.00506 – PubMed ID: 37535876
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Clin Colorectal Cancer. 2023 Jun 11
doi: 10.1016/j.clcc.2023.06.002 – PubMed ID: 37429749
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials
Eur J Cancer. 2023 Aug;
doi: 10.1016/j.ejca.2023.05.001 – PubMed ID: 37301718
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Clin Cancer Res. 2023 Jun 13
doi: 10.1158/1078-0432.CCR-22-3878 – PubMed ID: 37022350
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study.
J Immunother Cancer. 2023 Apr
doi: 10.1136/jitc-2022-006633 – PubMed ID: 37085190
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
Cancer Med. 2023 Apr
doi: 10.1002/cam4.5699 – PubMed ID: 36880426
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs’ development
Br J Cancer. 2023 Mar
doi: 10.1038/s41416-023-02180-7 – PubMed ID: 36759721
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials Journal
ESMO Open – 2022
doi 10.1016/j.esmoop.2022.100606 – PubMed ID: 36327757
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials Journal
European Journal of Cancer – 2022
doi 10.1016/j.ejca.2022.05.016 – PubMed ID: 35749909
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
Journal of Clinical Oncology – 2022
doi 10.1200/JCO.22.00839 – PubMed ID: 35666229
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
British Journal of Cancer – 2022
doi 10.1038/s41416-022-01852-0 – PubMed ID: 35665778
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
Lancet Oncol – 2022
doi 10.1016/S1470-2045(22)00274-1 – PubMed ID: 35636444
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies
European Journal of Cancer – 2022
doi 10.1016/j.ejca.2022.04.019 – PubMed ID: 35594613
Encorafenib plus cetuximab treatment in BRAF V600E mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series
European Journal of Cancer – 2022
doi 10.1016/j.ejca.2022.03.011 – PubMed ID: 35436675
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies
European Journal of Cancer – 2022
doi 10.1016/j.ejca.2022.02.031 – PubMed ID: 35366570
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature
Cancer Treatment Reviews – 2022
doi 10.1016/j.ctrv.2021.102326 – PubMed ID: 35016085
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO
ESMO Open – 2021
doi 10.1016/j.esmoop.2021.100293 – PubMed ID: 34689001
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications
Journal of the National Cancer Institute – 2021
doi 10.1093/jnci/djab169 – PubMed ID: 34469533
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study
European Journal of Cancer – 2021
doi 10.1016/j.ejca.2021.06.037 – PubMed ID: 34365081
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients
Clinical Colorectal Cancer – 2021
doi 10.1016/j.clcc.2021.07.001 – PubMed ID: 34364814